These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3814210)

  • 1. [Separation and pharmaco-toxicological studies of the enantiomers of Ifosfamide].
    Blaschke G; Hilgard P; Maibaum J; Niemeyer U; Pohl J
    Arzneimittelforschung; 1986 Oct; 36(10):1493-5. PubMed ID: 3814210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.
    Paprocka M; Kuśnierczyk H; Budzyński W; Rak J; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1986; 34(3):275-84. PubMed ID: 3592931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. II. Antiproliferative activity of cyclophosphamide and ifosfamide enantiomers.
    Paprocka M; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1986; 34(3):285-91. PubMed ID: 3592932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of acute toxicity and antitumor activity of IF-XXV preparation and holoxan.
    Kuśnierczyk H; Matuszyk J; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1989; 37(5-6):547-56. PubMed ID: 2487366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological evaluation of ifosfamide and its enantiomers in laboratory animals.
    Kleinrok Z; Chmielewska B; Czuczwar JS; Rajtar G; Sawiniec Z; Jarzabek G
    Arch Immunol Ther Exp (Warsz); 1986; 34(3):293-304. PubMed ID: 3592933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enantioselective cytotoxic activity of bromine-substituted analogues of ifosfamide. A microsomal implication.
    Hładoń B; Sloderbach A; Laskowska H
    Pol J Pharmacol; 1997; 49(2-3):127-36. PubMed ID: 9437759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antitumor activity of two ifosfamide analogs with a five-membered ring.
    Kutscher B; Niemeyer U; Engel J; Kleemann A; Hilgard P; Pohl J; Scheffler G
    Arzneimittelforschung; 1995 Mar; 45(3):323-6. PubMed ID: 7741794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological properties of racemic chlorobromofosfamide.
    Juszkiewicz M; Kleinrok Z; Sawiniec Z
    Arch Immunol Ther Exp (Warsz); 1994; 42(5-6):405-13. PubMed ID: 8572900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model.
    Wainer IW; Granvil CP; Wang T; Batist G
    Cancer Res; 1994 Aug; 54(16):4393-7. PubMed ID: 8044787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates.
    Kuśnierczyk H; Radzikowski C; Paprocka M; Budzyński W; Rak J; Kinas R; Misiura K; Stec W
    J Immunopharmacol; 1986; 8(4):455-80. PubMed ID: 3805744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, acute toxicity and chemotherapeutic anti-cancer activities of a new tripeptidic mustard.
    De Barbieri A; Dall'Asta L; Comini A; Springolo V; Mosconi P; Coppi G
    Farmaco Sci; 1983 Apr; 38(4):205-18. PubMed ID: 6861998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine.
    Voelcker G; Pfeiffer B; Schnee A; Hohorst H
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):74-8. PubMed ID: 10664245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice.
    Masurel D; Houghton PJ; Young CL; Wainer IW
    Cancer Res; 1990 Jan; 50(2):252-5. PubMed ID: 2295063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solutions.
    Gilard V; Martino R; Malet-Martino M; Niemeyer U; Pohl J
    J Med Chem; 1999 Jul; 42(14):2542-60. PubMed ID: 10411475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of p-Nitrobenzoic Acid (CAS No. 62-23-7) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 442():1-306. PubMed ID: 12595921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
    Kuśnierczyk H; Konarski L; Kowalski P; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
    Misiura K; Kinas RW; Stec WJ; Kusnierczyk H; Radzikowski C; Sonoda A
    J Med Chem; 1988 Jan; 31(1):226-30. PubMed ID: 3336021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers (author's transl)].
    Blaschke G; Kraft HP; Fickentscher K; Köhler F
    Arzneimittelforschung; 1979; 29(10):1640-2. PubMed ID: 583234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect and mode of action of 1-beta-D-arabinofuranosylcytosine 5'-phosphate in leukemia L1210.
    Schrecker AW; Goldin A
    Cancer Res; 1968 Apr; 28(4):802-3. PubMed ID: 5649067
    [No Abstract]   [Full Text] [Related]  

  • 20. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.